Navigation Links
Compounds Found to Protect Rabbits From Cerebral Palsy
Date:2/25/2009

Discovery called exciting, but human application remains elusive, expert says

WEDNESDAY, Feb. 25 (HealthDay News) -- In experiments with rabbits, a team of scientists has created two chemical compounds that appear to protect a fetus from developing cerebral palsy from a lack of oxygen.

"It is known that if you have too much nitric oxide in the brain, which can be produced during hypoxia, it leads to fetal neurodegeneration," said lead researcher Richard B. Silverman, a chemistry professor at Northwestern University.

If such an event occurs during pregnancy, it can lead to brain damage in the fetus that can result in cerebral palsy, Silverman said. "This can happen right at the end of pregnancy," he explained.

Common causes of hypoxia include a pinched umbilical cord or a cord wrapped around the fetus's neck or shoulder.

The report was published online Wednesday in the Annals of Neurology.

Silverman's team developed two compounds that block an enzyme in brain cells that produces nitric oxide. At normal levels, nitric oxide is a neurotransmitter, which is important for brain functioning, but at high levels it can damage brain tissue. An excess of nitric oxide in the brain is believed to play a role in cerebral palsy.

In experiments with rabbits, excess nitric oxide caused most of the fetuses to die, and those that survived were severely brain-damaged, Silverman said.

"If you administer the compounds that we made a half-hour prior to the hypoxic insult, you can protect the fetus from neurodegeneration," Silverman said. All the animals treated with the compounds lived, and those given placebo died. Among animals given just one of the compounds, up to 80 percent were born normal, Silverman said.

Silverman said that he thinks the compounds can be used to treat infants with compromised oxygen levels before cesarean delivery. "The sooner you can protect the fetal brain from nitric oxide, the less neurodegeneration you will have," he said.

The next step is to experiment with these compounds in sheep, Silverman said. "It's a long way to humans," he noted.

Dr. Ernest Graham, an assistant professor of maternal-fetal medicine at Johns Hopkins School of Medicine in Baltimore, agrees that using the compounds in clinical practice is a long way off.

"This is very exciting stuff," Graham said. However, he added, how it could be used remains elusive.

Graham said that perhaps the compounds could be used after delivery for infants who appear lethargic or "floppy," or have poor muscle tone, he said. Giving it before delivery would mean giving it to many babies who don't need it, he noted.

Using it before delivery on an infant with a prolapsed cord or similar problem might not be practical, Silverman said. "With these kids, things are moving so fast, I don't know it is going to be practical to give an additional drug," he said.

Cerebral palsy is caused by an injury to the brain before, during or shortly after birth, although it typically is not diagnosed until after the age of 1. Approximately 750,000 children and adults in the United States have a form of cerebral palsy, with most having been born with the condition.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on cerebral palsy.



SOURCES: Richard B. Silverman, Ph.D., John Evans Professor of Chemistry, Northwestern University, Evanston, Ill.; Ernest Graham, M.D., assistant professor, maternal-fetal medicine, Johns Hopkins School of Medicine, Baltimore; February 2009, Annals of Neurology


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Compounds that trigger beta cell replication identified by JDRF funded researchers
2. Stunning finding: Compounds protect against cerebral palsy
3. AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
4. New platinum-phosphate compounds kill ovarian cancer cells
5. Scientists exploring new compounds to target muscular dystrophy
6. University of Illinois - Chicago Study: Raisins Contain Compounds that May Inhibit Cavity-causing Bacteria
7. InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds
8. USPTO Issues Patent Embodying Methodologies for Abating a Broad Range of Allergens, Pathogens, Viruses, Bacteria, Odors and Volatile Organic Compounds.
9. Study Finds Spice-Rich Marinades Can Reduce Harmful Compounds When Grilling
10. ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds
11. Drugs With Marijuana Compounds Dont Boost Adverse Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 2017 , ... Journal of Oral Implantology – Tooth loss is ... dental health, including complications with speech, eating, and overcompensation of mouth due to the ... teeth. As the number of tooth replacements increase, it is imperative to design an ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/26/2017)... Gainesville, FL (PRWEB) , ... April 26, 2017 ... ... health and human performance, is proud to announce that it has received 510(k) ... cutting-edge technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... 18, 2017 Viverae ® , a leader ... integration of IBM ® Watson Campaign Automation, implementing ... communications for a personalized experience. Through digital engagement, the ... health in real time. The enhanced experience drives engagement ... members, wherever they are in their journey to health. ...
Breaking Medicine Technology: